FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
10 letters match. Newest first.
-
DrugsKath Khemicals LLC
FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.
High risk -
DrugsLaboratoire Druide Inc.
FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.
High risk -
DrugsEurosirel S.P.A
FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.
High risk -
DrugsSeoul Cosmetics Co., Ltd.
FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.
High risk -
DrugsAvaria Health & Beauty Corp.
FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.
High risk -
DrugsTan Alize Kozmetik Ve Temizlik Urunleri
FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.
High risk -
DrugsNeilMed Pharmaceuticals Inc.
FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.
High risk -
DrugsChampaklal Maganlal Homeo Pharmacy Private Limited
FDA says Champaklal Maganlal Homeo Pharmacy's Bebelyn diarrhea and colic products are unapproved new drugs for infants.
High risk -
DrugsChampaklal Maganlal Homeo Pharmacy Private Limited
Champaklal Maganlal Homeo Pharmacy failed to test each glycerin lot for identity, including DEG/EG, in OTC and homeopathic drugs.
High risk -
DrugsProfessional Compounding Centers of America dba PCCA
PCCA received adulterated drug ingredients from suppliers on FDA import alerts and failed adequate glycerin identity testing.
High risk